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Introduction {#sec1}
============

Neurons of the central nervous system (CNS) are generated during finite windows of neurogenesis that occur as tightly orchestrated processes during embryonic development. In the mammalian CNS, all the projection neurons are produced during this developmental period; however, the production of certain types of interneurons persists throughout life in two neurogenic niches in the postnatal brain: the subventricular zone (SVZ) that lines the lateral ventricles and the subgranular zone (SGZ) adjacent to the dentate gyrus of the hippocampus (for review see [@bib1]). In both cases, stem cells within the SGZ and SVZ neurogenic regions give rise to granular interneurons, which will replenish granule cell layers in the hippocampal dentate gyrus and the olfactory bulb, respectively, as part of ongoing homeostatic processes in the healthy brain.

Whether or not these stem cells can additionally give rise to other neuronal subtypes under certain pathological circumstances, for example, in response to brain injury, remains controversial. Studies in the early 2000s reported that significant neuronal loss through damage to areas adjacent to neurogenic niches could redirect the fate of stem cell-derived neuroblasts to not only migrate to the damaged area but also differentiate into regionally appropriate neuronal subtypes including midbrain dopamine neurons ([@bib32]), CA1 pyramidal neurons ([@bib22]), and medium spiny projection (MSP) neurons ([@bib4], [@bib24]). However, these findings have not been widely replicated and subsequent studies reported that projection neurons such as midbrain dopamine ([@bib11]) and medium spiny subtypes could not be generated following injury to the adult brain ([@bib16]). The study by [@bib16] reported that injury to the striatum can indeed elicit a response from the adjacent SVZ, including an increase in proliferation of precursor cells and a redirection of the migratory path of newborn neuroblasts away from their trajectory toward the olfactory bulb and instead toward the striatal site of injury where they can differentiate into mature neurons. Interestingly, however, phenotypic analysis indicated that they did not have the capacity to change differentiation potential to adopt a striatal projection neuron identity, but rather retained their identity as olfactory bulb interneurons in an ectopic location.

Striatal MSP neurons are generated from ventricular zone (VZ) progenitor cells through a peak phase of neurogenesis during embryonic development ([@bib9], [@bib23], [@bib27]). As development proceeds and the embryonic VZ transitions to the postnatal SVZ, the differentiation potential of VZ stem cells progressively shifts away from producing MSP neurons in favor of the olfactory bulb interneurons that continue to be generated throughout adult life ([@bib18], [@bib2]). Recently we reported that the tail end of the neurogenic program for production of MSPs persists into the early neonatal period, such that SVZ cells that have shifted predominately to the generation of olfactory bulb interneurons will also continue to contribute MSP neurons to the striatum over the first postnatal week ([@bib28]). This led us to hypothesize that injury-induced regeneration of striatal projection neurons may be most likely during this early postnatal period, when proliferating SVZ precursors remain competent for production of MSPs.

To test this, we compared the phenotype of newborn neurons in the neonatal and adult rat striatum following an ischemic striatal injury causing widespread loss of striatal MSPs. A combination of automated cell counting and manual inspection of orthogonal reconstructions to unambiguously assess co-localization of markers of cell phenotype allowed us to characterize thousands of newborn cells with respect to neuronal differentiation properties after injury to neonatal or adult striatum, respectively. The results suggest that striatal injury does not stimulate striatal neuron replacement, even during periods of active striatal neurogenesis.

Results {#sec2}
=======

Ischemic Damage to the Adult Striatum Induces Cellular Proliferation and Neurogenesis {#sec2.1}
-------------------------------------------------------------------------------------

Injection of the vasoconstrictor ET-1 produced an ischemic injury at the site of injection, resulting in an infarcted region characterized by loss of NeuN+ neurons throughout the dorsal head of the striatum ([Figure 1](#fig1){ref-type="fig"}A). Dividing cells were labeled by daily injection of 5-bromo-2′-deoxyuridine (BrdU) (100 mg/kg), and animals were perfused for histology 3 weeks after the final BrdU injection (4 weeks after injury). [Figures 1](#fig1){ref-type="fig"}B and 1C--1G show immunohistochemistry for BrdU, NeuN, and Darpp32 and the automated detection and digital annotation of BrdU for saline- and ET-1-treated animals, respectively, using the spot creation module in Imaris 9.0. The representative images show the significant proliferative response and accumulation of BrdU+ cells (red) in the immediate vicinity of the injured area defined by loss of NeuN+/Darpp32+ cells in ET-1-injected animals relative to saline-injected controls. The total number of BrdU+ cells was significantly greater in ET-1-injected animals compared with saline controls (saline: 98,990 ± 13,328 cells/mm^3^, ET-1: 838,600 ± 143,989 cells/mm^3^, data represent mean ± SEM, n = 6/group; p value = 0.0035) ([Figure 1](#fig1){ref-type="fig"}H). Due to loss of tissue volume following ischemia, we also represented BrdU+ cells (throughout this study) as a density of striatal tissue, which again showed a significant increase following ET-1 injection compared with saline (saline: 11,581 ± 1,944 cells/mm^3^, ET-1: 120,627 ± 26,087 cells/mm^3^, p value = 0.0085; [Figure 1](#fig1){ref-type="fig"}I).Figure 1Proliferation and Striatal Neurogenesis Is Increased 4 Weeks after Ischemic Injury to the Adult Striatum(A--K) (A) Immunohistochemistry for NeuN shows extensive cell loss associated with striatal ischemic injury at the level of ET-1 injection. Representative striatal sections immunohistochemically labeled for BrdU (red), NeuN (green), and Darpp-32 (blue) from saline (B) and ET-1 (C) groups illustrate the automated detection of BrdU+ cells and annotation as red spheres by Imaris software. The boxed area is represented at higher magnification without (D and F) and with annotation (E and G). The absolute number of BrdU+ cells (H) and the density of BrdU+ cells (I) are significantly increased following ET-1 injection. The absolute number of BrdU+/NeuN + cells (J) and BrdU+/NeuN+ density (K) are significantly increased in the ET-1-injected group compared with saline control. (L) Schematic sections (+1.70 mm, +1.20 mm and +0.70 mm from bregma) illustrate the approximate location of BrdU+/NeuN+ cells cumulatively across all animals from the saline (green dots, n = 6) and ET-1 (pink dots, n = 6) groups.Statistical analysis: (H) Welch\'s t test *t*(5.056) = 4.169, p = 0.0085, n = 6. (I) Welch\'s t test *t*(5.086) = 5.115, p = 0.0035, n = 6. (J) Welch\'s t test *t*(12.45) = 3.650, p = 0.0031, n = 12. (K) Welch\'s t test *t*(11.88) = 3.794, p = 0.0026, n = 12. ∗∗p \< 0.01; Error bars: Standard deviation.Scale bars: 500 μm in (A--C).BrdU, 5-bromo-2′-deoxyuridine.

To determine the effect of injury on striatal neurogenesis, cells co-expressing both BrdU and the mature neuronal marker NeuN were quantified in the anterior head of the striatum at an interval of 1:12 between 1.7 and 0.7 mm relative to bregma. Compared with the saline-injected animals, the total number of BrdU+/NeuN+ cells in this anterior striatum was significantly greater in ET-1-injected animals (saline: 26 ± 8 cells; ET-1: 136 ± 29 cells, mean ± SEM, n = 12/group; p value = 0.0031), as was the density of striatal BrdU+/NeuN+ cells (saline: 3 ± 0.84 cells/mm^3^, ET-1: 19 ± 4.19; p value = 0.0026) ([Figures 1](#fig1){ref-type="fig"}J and 1K). The number of BrdU+/NeuN+ cells across both groups was overall low and quite variable, with most of these cells remaining in close proximity to the rostral migratory stream ([Figure 1](#fig1){ref-type="fig"}L).

Newborn Neurons following Ischemic Injury Do Not Acquire a Medium Spiny Neuron Identity {#sec2.2}
---------------------------------------------------------------------------------------

To determine the phenotypic identity of newborn neurons residing in the striatum following ischemic injury, we first assessed co-labeling of BrdU+/NeuN+ cells for the MSP neuron marker, Darpp32. Evaluation of orthogonal reconstructions of cells acquired by confocal microscopy across 12 brains did not reveal any examples of BrdU+/NeuN+ cells that also expressed Darpp32. Interestingly however, a strikingly common occurrence was the presence of BrdU+ cells in tight apposition to Darpp32+/NeuN+ cells ([Figures 2](#fig2){ref-type="fig"}A--2J). From a top-down perspective in the x-y plane these cells often presented as triple-labeled, as seen in [Figures 2](#fig2){ref-type="fig"}A and 2F, but orthogonal inspection on the y axis showed the nuclei to be distinctly separate ([Figures 2](#fig2){ref-type="fig"}E and 2J). We also observed examples at the direct site of infarction, which initially appeared as triple-labeled; however, these were subsequently shown to auto-fluoresce across all emission wavelengths and deemed non-specific (not shown). In our experience this is a common feature of immunohistochemical analysis in areas where there is significant damage-induced necrosis and inflammation, often associated with infiltration of blood cells.Figure 2Ischemic Damage to the Adult Striatum Recruits Calretinin+ Interneurons but Not Medium Spiny Neurons(A--E) and (F--J) show two examples of immunohistochemistry for BrdU (red), NeuN (green), and Darpp32 (blue) at 4 weeks after ischemia, where BrdU+ cells appear to be co-registered with Darpp32+ neurons when viewed on the x-y axes but are revealed to be adjacent and non-overlapping through orthogonal reconstruction of the z axis. Orthogonal examination of immunohistochemistry for BrdU (red), NeuN (green), and calretinin (blue) revealed the presence of new calretinin+ neurons including both NeuN+ (K--O) and NeuN- (P--T) examples. Quantification showed BrdU+/CR+ absolute number (U), BrdU+/CR+ density (V), BrdU+/NeuN+/CR+ absolute number (W), and BrdU+/NeuN+/CR+ density (X) are all significantly increased following ET-1 injection compared with saline controls.Statistical analysis: (U) Unpaired t test *t*(10) = 2.373, p = 0.0391, n = 6. (V) Unpaired t test *t*(10) = 2.484, p = 0.0323, n = 6. (W) Welch\'s t test *t*(5.182) = 2.668, p = 0.0429, n = 6. (X) Welch\'s t test *t*(5.117) = 2.581, p = 0.0483, n = 6. ∗p \< 0.05; Error bars: Standard deviation.Scale bars: 25μm in (A--T).BrdU, 5-bromo-2′-deoxyuridine; CR, calretinin; Darpp32, dopamine- and cyclic-AMP-regulated phosphoprotein of molecular weight 32,000.

Immunohistochemical detection of calretinin (CR; [Figures 2](#fig2){ref-type="fig"}K--2T), a calcium-binding protein found in interneurons, including those normally destined for the olfactory bulb, revealed the presence of both BrdU+/CR+/NeuN- ([Figures 2](#fig2){ref-type="fig"}K--2O) and BrdU+/CR+/NeuN+ cells ([Figures 2](#fig2){ref-type="fig"}P--2T) in sham and ET-1-treated animals. Overall, around 61 ± 15% (mean ± SEM) of BrdU+/CR + cells were also NeuN+. Quantification showed that the ET-1-treated animals had a significant increase in total BrdU+/CR+ cell number (saline: 54 ± 15.41 cells, ET-1: 136 ± 30.93 cells, data represent mean ± SEM, n = 6/group, p = 0.0391) ([Figure 2](#fig2){ref-type="fig"}U) and BrdU+/CR+ cell density (saline: 5.82 ± 1.53 cells/mm^3^, ET-1: 19.75 ± 5.39 cells/mm^3^, p = 0.0323) ([Figure 2](#fig2){ref-type="fig"}V). We also observed a significant increase in BrdU+/NeuN+/CR+ cell number in the injury group (saline: 10 ± 4.8 cells; ET-1: 106 ± 35.6 cells, p = 0.0429) ([Figure 2](#fig2){ref-type="fig"}W) and BrdU+/NeuN+/CR+ cell density (saline: 1.20 ± 0.61 cells/mm^3^, ET-1: 15.96 ± 5.68 cells/mm^3^, p = 0.0483) ([Figure 2](#fig2){ref-type="fig"}X).

Ischemic Damage to the Neonatal Striatum Does Not Induce Striatal Neurogenesis {#sec2.3}
------------------------------------------------------------------------------

Injection of ET-1 at postnatal day 1 produced a robust ischemic injury to the striatum and overlying cortex, manifesting at 4 weeks as hydrocephaly, significant striatal atrophy, and cortical scarring with conspicuous mushroom-like patterns reminiscent of ulegyric folding seen in cerebral palsy ([Figure 3](#fig3){ref-type="fig"}A). Immunohistochemistry for BrdU, NeuN, and Darpp32 cells showed a robust level of proliferation in both saline- ([Figure 3](#fig3){ref-type="fig"}B) and ET-1- ([Figure 3](#fig3){ref-type="fig"}C) treated neonatal animals during the first week after surgery. The absolute number of BrdU+ cells was significantly higher in the saline control group (saline: 603,348 ± 27,413; ET-1: 401,558 ± 15,668, data represent mean ± SEM, n = 6/group, p \< 0.0001; [Figure 3](#fig3){ref-type="fig"}D); however, the ET-1 group had a significantly higher density of BrdU+ cells given the substantial striatal atrophy associated with the injury (saline: 78,685 ± 1,806 cells/mm^3^; ET-1: 110,657 ± 2,257 cells/mm^3^, p \< 0.0001; [Figure 3](#fig3){ref-type="fig"}E).Figure 3Ischemic Damage to the Neonatal Brain Does Not Increase Gross Striatal Neurogenesis 4 Weeks After Injury(A--H) (A) Immunohistochemistry for NeuN in representative sections illustrates typical cortical malformation and striatal atrophy at 4 weeks following ischemic damage in the neonatal brain. Representative striatal sections immunohistochemically labeled for BrdU (red), NeuN (green), and Darpp-32 (blue) from saline (B) and ET-1 (C) groups illustrate the automated detection of BrdU+ cells and annotation as red spheres by Imaris software. Four weeks following injection of ET-1 in the neonatal striatum, the absolute number of BrdU+ cells (D) is significantly reduced compared with saline controls; however, the density of BrdU+ cells (E) is significantly increased. Double-labeling for NeuN showed that the absolute number of BrdU+/NeuN+ cells (F) and the BrdU/NeuN density (G) are not significantly different between ET-1 and saline groups 4 weeks post ischemia. (H) Schematic sections through the striatum illustrating the approximate location of BrdU+/NeuN+ cells (pink dots) cumulatively across all animals from the saline (n = 6) and ET-1 (n = 6) groups.Statistical analysis: (D) Unpaired t test *t*(10) = 6.391, p \< 0.0001, n = 6. (E) Unpaired t test *t*(10) = 11.06, p \< 0.0001, n = 6. (F) Welch\'s t test *t*(12.32) = 0.9198, p = 0.3754, n = 12 for ET-1 and n = 11 for control. (G) Unpaired t test *t*(21) = 1.57, p = 0.1314, n = 12 for ET-1 and n = 11 for control. ∗∗∗∗p \< 0.0001; Error bars: Standard deviation.Scale bars: 500 μm in (A--C).BrdU, 5-bromo-2′-deoxyuridine.

Newborn neurons generated in the first week after saline or ET-1 injection were identified based on co-expression of BrdU and NeuN as described for the adult groups. Quantification at three striatal levels in coronal sections showed no significant difference in BrdU+/NeuN+ cells between saline- and ET-1-treated animals, either in absolute number (saline: 504 ± 127 cells, n = 11; ET-1: 381 ± 43 cells, n = 12, p = 0.3754; [Figure 3](#fig3){ref-type="fig"}F) or striatal density (saline: 70.6 ± 18.4 cells/mm^3^; ET-1: 105.7 ± 13.1 cells/mm^3^, n = 12, p = 0.1314; [Figure 3](#fig3){ref-type="fig"}G). The new BrdU+/NeuN+ neurons were found predominately in close proximity to the SVZ and rostral migratory stream (RMS) and also notably in the deeper parenchyma of the nucleus accumbens, in close proximity to the anterior commissure ([Figure 3](#fig3){ref-type="fig"}H). The pattern of distribution was similar in saline and ET-1-treated animals.

The Production of Darpp32+ Striatal Neurons in the Early Neonatal Period Is Not Affected by Striatal Injury {#sec2.4}
-----------------------------------------------------------------------------------------------------------

New Darpp32+ striatal projection neurons generated in the first week after ET-1 or control saline injection into the neonatal striatum were identified by validation of co-expression of BrdU, NeuN, and Darpp32+ in orthogonal re-constructions of confocal images ([Figures 4](#fig4){ref-type="fig"}A--4E). Quantification did not reveal any difference between ET-1-treated and saline-animals in either the absolute number (saline: 42 ± 11 cells; ET-1: 46 ± 24 cells, mean ± SEM, n = 6/group, p = 0.8806; [Figure 4](#fig4){ref-type="fig"}F) or density (saline: 5.91 ± 1.74 cells/mm^3^; ET-1: 11.63 ± 5.44 cells/mm^3^, n = 6/group, p = 0.3554; [Figure 4](#fig4){ref-type="fig"}G) of BrdU+/NeuN+/Darpp32+ cell density in the striatum 4 weeks after surgery. In both groups, the BrdU+/NeuN+/Darpp32+ cells were found close to the SVZ and in the nucleus accumbens ([Figure 4](#fig4){ref-type="fig"}H).Figure 4Neonatal Ischemia Does Not Influence the Constitutive Production of Medium Spiny Projection Neurons 4 Weeks after Injury(A--G) (A--E) Orthogonal reconstruction of immunohistochemical labeling for BrdU (red), NeuN (green), and Darpp32 (blue) identifies that new BrdU+/NeuN+/Darpp32+ neurons are generated during the early neonatal period. The absolute numbers (F) and the densities (G) of BrdU+/NeuN+/Darpp32+ cells were not significantly different between ET-1- and saline-injected groups.(H) Schematic sections illustrating the approximate location of BrdU+/NeuN+ cells (pink dots) and BrdU+/NeuN+/Darpp-32+ cells (green dots) cumulatively across all animals from the saline (n = 5) and ET-1 (n = 6) groups.(I--V) (I--M) Immunohistochemical labeling showed that a population of BrdU+/CR+ cells (red and blue, respectively) that did not express NeuN (green) was actively generated in the neonatal brain. The absolute number of BrdU+/CR+/NeuN- cells was significantly greater in the ET-1 group compared with saline controls (N) but the density was unchanged (O). A second population of newly generated BrdU+/CR+ that did express NeuN could also be identified in the neonatal brain (P--T). The absolute numbers (U) of BrdU+/NeuN+/CR+ cells and the densities (V) were not significantly different between the ET-1 and saline control groups at 4 weeks.Statistical analysis: (F) Unpaired t test *t*(10) = 0.1541, p = 0.8806, n = 6. (G) Welch\'s t test *t*(6.009) = 1.001, p = 0.3554, n = 6. (N) Welch\'s t test *t*(4.554) = 3.989, p = 0.0126, n = 5 for sham and n = 6 for ET-1. (O) Unpaired t test *t*(9) = 1.653, p = 0.1327, n = 5 for sham and n = 6 for ET-1. (U) Unpaired t test *t*(9) = 2.435, p = 0.0376, n = 5 for sham and n = 6 for ET-1. (V) Welch\'s t test *t*(5.507) = 3.246, p = 0.0198, n = 5 for sham and n = 6 for ET-1. ∗p \< 0.05; Error bars: Standard deviation.Scale bars: 25 μm in (A--E) and 50 μm in (I--M) and (P--T).BrdU, 5-bromo-2′-deoxyuridine; Darpp32, dopamine- and cyclic-AMP-regulated phosphoprotein of molecular weight 32,000; CR, calretinin.

Analysis of immunohistochemistry for CR showed the presence of BrdU+/CR+/NeuN- cells ([Figures 4](#fig4){ref-type="fig"}I--4M) in both ET-1- and saline-injected animals. Quantification at 4 weeks showed that there was significantly more BrdU+/CR+ cells in the control group compared with the ET-1-treated animals (saline: 806.4 ± 128.6 cells, n = 5; ET-1: 276 ± 33.8 cells, n = 6, p = 0.0126; [Figure 4](#fig4){ref-type="fig"}N), although there was no difference between the two groups when represented as striatal density (saline: 114.4 ± 20.4 cells/mm^3^; ET-1: 77.4 ± 11.5 cells/mm^3^, n = 6, p = 0.1327; [Figure 4](#fig4){ref-type="fig"}O). We also identified BrdU+/CR+/NeuN+ cells ([Figures 4](#fig4){ref-type="fig"}P--4T), with quantification showing that ET-1 treatment led to a significant increase in absolute number (saline: 64.8 ± 18.8 cells, n = 5; ET-1: 170 ± 35.9 cells, n = 6, p = 0.0376; [Figure 4](#fig4){ref-type="fig"}U) and striatal density (saline: 9.27 ± 2.70 cells/mm^3^, n = 5; ET-1: mean ± SEM = 48.97 ± 11.93 cells/mm^3^, n = 6, p = 0.0198; [Figure 4](#fig4){ref-type="fig"}V).

To assess whether neonatal ischemic damage affected striatal neurogenesis that manifested over a more protracted timeline following the injury, we examined the ET-1 and saline groups with a longer 12-week chase period following the 1-week BrdU pulse. The ET-1-induced ischemic pathology appeared similar to the assessment at 4 weeks, with hydrocephaly, striatal atrophy, and glial scarring in the striatum and overlying cortex ([Figure 5](#fig5){ref-type="fig"}A). Immunohistochemical analysis showed robust labeling of BrdU+ cells in both the saline control ([Figure 5](#fig5){ref-type="fig"}B) and ET-1 ([Figure 5](#fig5){ref-type="fig"}C) groups. The number of BrdU+ cells was significantly reduced in the ET-1 group (saline: 37,891 ± 3,249 cells; ET-1: = 40,363 ± 4,070 cells, mean ± SEM, n = 5/group, p = 0.6477; [Figure 5](#fig5){ref-type="fig"}D), although not when represented as striatal density given the substantial atrophy in the ET-1 group (control: 347,863 ± 25,334 cells/mm^3^; ET-1: 216,310 ± 32,005 cells/mm^3^, p = 0.0122; [Figure 5](#fig5){ref-type="fig"}E). The number of new, BrdU+/NeuN+ neurons generated in the first week after saline or ET-1 injection and surviving to 12 weeks was also lower in ET-1 animals, although not significantly (saline: mean ± SEM = 696 ± 84.21 cells, n = 5; ET-1: mean ± SEM = 831 ± 95.19 cells, n = 5, p = 0.3214; [Figure 5](#fig5){ref-type="fig"}F) and the striatal density was similar in the ET-1 and control groups (saline: mean ± SEM = 6,386 ± 728.96 cells/mm^3^, n = 5; ET-1: mean ± SEM = 4,418 ± 663.30 cells/mm^3^, n = 5, p = 0.0809; [Figure 5](#fig5){ref-type="fig"}G). The topographical distribution of new neurons was similar to that observed at 4 weeks, predominately close to the SVZ and in the nucleus accumbens ([Figure 5](#fig5){ref-type="fig"}H), although clearly in greater numbers.Figure 5Ischemic Damage to the Neonatal Brain Does Not Increase Gross Striatal Neurogenesis 12 Weeks after Injury(A--G) (A) Immunohistochemistry for NeuN in representative sections illustrates typical cortical malformation and striatal atrophy at 12 weeks following ischemic damage in the neonatal brain. Representative striatal sections immunohistochemically labeled for BrdU (red), NeuN (green), and Darpp-32 (blue) from saline (B) and ET-1 (C) groups illustrate the automated detection of BrdU+ cells and annotation as red spheres by Imaris software. Twelve weeks following injection of ET-1 in the neonatal striatum, the absolute number of BrdU+ cells (D) is significantly reduced compared with saline controls; however, the density of BrdU+ cells (E) is unchanged. Double-labeling for NeuN showed that the absolute number of BrdU+/NeuN+ cells (F) and the BrdU/NeuN density (G) are not significantly different between ET-1 and saline groups 12 weeks post-ischemia. (H) Schematic sections through the striatum illustrate the approximate location of BrdU+/NeuN+ cells (pink dots) cumulatively across all animals from the saline (n = 6) and ET-1 (n = 6) groups.Statistical analysis: (D) Unpaired t test *t*(8) = 3.223, p = 0.0122, n = 5. (E) Unpaired t test *t*(8) = 0.4747, p = 0.6477, n = 5. (F) Unpaired t test *t*(8) = 1.997, p = 0.0809, n = 5. (G) Unpaired t test *t*(8) = 1.057, p = 0.3214, n = 5. ∗p \< 0.05; Error bars: Standard deviation.Scale bars: 500 μm in (B and C).BrdU, 5-bromo-2′-deoxyuridine.

As per the 4-week groups, BrdU+/NeuN+ cells present at 12 weeks were assessed for co-expression of phenotypic markers Darpp32 ([Figures 6](#fig6){ref-type="fig"}A--6H) and CR ([Figures 6](#fig6){ref-type="fig"}I--6V). Quantification showed that there was no significant difference in the number of BrdU+/NeuN+/Darpp32+ neurons in ET-1-injured or saline control groups (saline: 3,403 ± 507 cells; ET-1: 2,095 ± 446 cells, mean ± SEM, n = 5/group, p = 0.089; [Figure 6](#fig6){ref-type="fig"}F) or their striatal density (saline: 370.2 ± 56.6 cells/mm^3^; ET-1: 388.1 ± 66.9 cells/mm^3^, p = 0.8425; [Figure 6](#fig6){ref-type="fig"}G). The distribution of BrdU+/NeuN+/Darpp32+ neurons at 12 weeks ([Figure 6](#fig6){ref-type="fig"}H) was similar to the pattern observed at 4 weeks, although there were clearly greater numbers at 12 weeks and a more greater representation in the deeper striatal parenchyma, more distal to the SVZ.Figure 6Neonatal Ischemia Does Not Influence the Constitutive Production of Medium Spiny Projection Neurons 12 Weeks after Injury(A--G) (A--E) Orthogonal reconstruction of immunohistochemical labeling for BrdU (red), NeuN (green), and Darpp32 (blue) identify new BrdU+/NeuN+/Darpp32+ neurons generated during the early neonatal period. The absolute numbers (F) and the densities (G) of BrdU+/NeuN+/Darpp32+ cells were not significantly different between ET-1- and saline-injected groups.(H) Schematic sections (+1.70 mm, +1.20 mm, and +0.70 mm from bregma) illustrate the approximate location of BrdU+/NeuN+ cells (pink dots) and BrdU+/NeuN+/Darpp-32+ cells (green dots) cumulatively across all animals from the saline (n = 5) and ET-1 (n = 5) groups.(I--V) (I--M) Immunohistochemical labeling showed a population of BrdU+/CR+ cells (red and blue, respectively) that did not express NeuN (green) was actively generated in the neonatal brain. Both the absolute number (N) and density (O) of BrdU+/CR+/NeuN- cells was not significantly different between ET-1 and saline control groups. A second population of newly generated BrdU+/CR+ that did express NeuN could also be identified in the neonatal brain (P--T). The absolute number (U) of BrdU+/NeuN+/CR+ cells and the average density (V) were not significantly different between the ET-1 and saline control groups at 12 weeks.Statistical analysis: (F) Unpaired t test *t*(8) = 1.936, p = 0.0888, n = 5. (G) Unpaired t test *t*(8) = 0.2053, p = 0.8425, n = 5. (N) Unpaired t test *t*(8) = 0.3619, p = 0.7268, n = 5. (O) Welch\'s t test *t*(4.252) = 1.049, p = 0.3501, n = 5. (U) Unpaired t test *t*(8) = 0.1186, p = 0.9085, n = 5. (V) Welch\'s t test *t*(4.322) = 1.313, p = 0.2545, n = 5. Error bars: Standard deviation.Scale bars: 25 μm in (A--E), (I--M), and (P--T).BrdU, 5-bromo-2′-deoxyuridine; Darpp32, dopamine- and cyclic-AMP-regulated phosphoprotein of molecular weight 32,000; CR, calretinin.

Similarly, neither was there significant difference in the absolute number (saline: mean ± SEM = 38.90 ± 4.46 cells/mm^3^, n = 5; ET-1: mean ± SEM = 65.66 ± 25.11 cells/mm^3^, n = 5, p = 0.3501; [Figure 6](#fig6){ref-type="fig"}N) or density (saline: mean ± SEM = 357.6 ± 36.67 cells, n = 5; ET-1: mean ± SEM = 319.2 ± 99.58 cells, n = 5, p = 0.7268; [Figure 6](#fig6){ref-type="fig"}O) of BrdU+/CR+/NeuN- cells nor was there a significant difference in the number (control: mean ± SEM = 170.4 ± 24.71 cells, n = 5; ET-1: mean ± SEM = 177.6 ± 55.43 cells, n = 5, p = 0.9085; [Figure 6](#fig6){ref-type="fig"}U) or density (control: mean ± SEM = 18.41 ± 2.69 cells/mm^3^, n = 5; ET-1: mean ± SEM = 36.32 ± 13.37 cells/mm^3^, n = 5, p = 0.2545; [Figure 6](#fig6){ref-type="fig"}V) of BrdU+/CR+/NeuN+ cells.

Discussion {#sec3}
==========

Research on adult neurogenesis in the mammalian brain has often been controversial, ranging from recent lack of consensus as to whether it continues at all in the human brain after the early postnatal period ([@bib17]) to the present topic regarding the capacity of injury to stimulate regeneration of neuronal subtypes that are normally only produced during embryonic development. Here we have used an approach combining software-automated identification of BrdU+ cells co-labeled for markers of phenotypic identity followed by manual verification in orthogonal reconstructions, to screen thousands of newborn cells generated following striatal ischemia in neonatal or adult rats. The results indicate that loss of striatal projection neurons does not trigger their replacement through a neurogenic "self-repair" process.

The widespread loss of striatal neurons following injection of ET-1 into the adult forebrain is consistent with the pattern of ischemic damage we ([@bib10], [@bib26]) and others ([@bib12]) have previously reported and shown to be associated with a deficit in motor function that is stable over months. The robust proliferative response to injury, shown as a significant increase in BrdU+ cells relative to saline-treated controls, is a well-described response to acute brain injuries ([@bib5], [@bib21], [@bib30]) including those arising from ischemic damage ([@bib4], [@bib16], [@bib24]). Automated analysis of whole striatal sections captured as three-dimensional tissue volumes using confocal microscopy and Imaris 9.1 allowed us to identify and examine a total of ∼420,000 BrdU+ cells across 6 ET-1-treated animals and ∼50,000 BrdU-labeled cells across 6 animals in the saline control group. The BrdU dosing regimen of 50 mg/kg at 12-h intervals has previously been shown to capture all dividing cells during the pulse period ([@bib4]) and likely represented the overwhelming majority of cells born in the first week after injury.

The significant increase in newborn cells in the adult striatum adopting a neuronal (BrdU+/NeuN+) identity after ischemic injury is consistent with many previous studies reporting striatal neurogenesis in response to stroke ([@bib4], [@bib24], [@bib34], [@bib33]) and appears to be a broadly conserved physiological response to acute striatal injury with similar observations following excitotoxic lesions ([@bib7], [@bib30]) or trauma ([@bib6]). Whether these new neurons can contribute to recovery remains an open question. Although there have been some correlative studies on the magnitude of neurogenesis and post-stroke recovery (for review see [@bib19]), there is no clear causal link. New neurons accounted for only a small fraction of the proliferative response to injury to the adult striatum, with NeuN+/BrdU+ cells representing only ∼0.00014% of all BrdU+ cells. The distribution of these cells located close to the SVZ but also dorsally, adjacent to the RMS, suggests that in addition to proliferation and migration of SVZ cells, neuroblasts already en route to the olfactory bulb via the RMS can divert ventrally into the striatal parenchyma. It is unknown whether this affects the normal contribution of these cells to the olfactory bulb, and this may be worth investigating in future studies. Although we did not look beyond neuronal phenotype to characterize the remaining BrdU+ cells in the present study, we ([@bib14], [@bib30]) and others ([@bib3], [@bib20]) have previously reported that many of these are locally dividing glial cells in the striatal parenchyma, including up to 40% microglia.

Although no newborn neurons generated after ischemia in adult rats were found to co-label with the striatal projection neuron marker Darpp32, many were found to be closely apposed to Darpp32+ neurons and some were also found to label non-specifically at the site of infarction. There were, however, many examples of new BrdU+ neurons that co-expressed CR, consistent with an interneuron identity. These observations are in line with those from studies where we ([@bib30]) and others ([@bib16]) have previously reported a lack of neuronal differentiation into striatal projection neurons following injury and supports the idea that striatal damage can redirect olfactory-bound neuroblasts from the SVZ and RMS toward the site of damage, but without changing their intrinsic capacity for differentiation as granular layer interneurons.

This led us to consider that replacement of striatal projection neurons following damage may depend on the presence of progenitors competent for production of these neurons at the time of injury. Although the bulk of MSN production in the rodent brain occurs embryonically, with a peak production between embryonic days 12--17 ([@bib9], [@bib23], [@bib27]), the tail end of this neurogenic program extends into the early postnatal period ([@bib28]). Injection of ET-1 into the striatum in neonatal rats produced an ischemic injury manifesting at 4 and 12 weeks as striatal atrophy with concomitant hydrocephaly as well as malformation of the overlying cortex. We have recently shown that this model captures various elements relevant for pre-term brain injury leading to cerebral palsy, such as white matter damage and motor deficit ([@bib29]).

To assess the impact of striatal injury on neurogenesis during this early postnatal period, birth-dating was performed over the first week after ET-1 injection and histology was performed at both 4 and 12 weeks to allow for the possibility of a delayed or protracted response. Large numbers of BrdU+ cells were seen in saline-injected control animals, reflecting the high rate of proliferation in the neonatal brain. Although the absolute number of BrdU+ cells was in fact greater in saline compared with ET-1-treated animals this likely reflects the smaller striatal volume due to ET-1-induced atrophy. In support of this, when represented as a density, BrdU+ cell numbers were greater in the ET-1 group at 4 weeks. Immunohistochemical analysis showed the presence of BrdU+/NeuN+ neurons in all animals and included both Darpp-32+ and CR+ subtypes as we have previously reported in naive animals ([@bib28]). In both saline- and ET-1-treated animals, these new neurons were distributed predominately around the SVZ and RMS, but unlike the adult groups, they were also distributed throughout the deeper striatal parenchyma, particularly in and around the anterior commissure. This is in line with previous studies showing the persistence of striatal neurogenesis in the uninjured postnatal mammalian brain, including production of GABAergic interneurons ([@bib8], [@bib13], [@bib25]) and more recently, striatal projection neurons ([@bib28]), which declines sharply in the first week after birth.

The number of new striatal neurons was not significantly affected by neonatal ischemic injury when measured at 4 or 12 weeks and, importantly, this was also the case when looking at the subset of DARPP32+ neurons. Thus, even in the early neonatal period when there are actively dividing SVZ precursors producing striatal projection neurons, striatal ischemia does not stimulate the additional recruitment of these neurons to replace those lost to the injury. The very early age at which the injury occurred in the present study (P1) is significant because it corresponds to an active phase of production of DARPP32+, which we have previously shown declines sharply by P5 ([@bib28]). Similar studies of hypoxic-ischemic damage in the neonatal period have also reported a lack of new DARP32+ neurons, but have been performed at ages beyond P5 and after a perceptible period of neurogenesis for this cell types ([@bib31]). Not only the number of Darpp32+/BrdU+ neurons but also their topographical distribution remains remarkably consistent across the control and ET-1 groups, further supporting the conclusion that the ongoing neurogenic program is essentially impervious to injury. The increase in CR+/NeuN+/BrdU+ cells at 4 weeks suggests a redirection of olfactory-bound neuroblasts in a manner similar to that observed after injury to the adult brain. This was no longer evident at 12 weeks, which may indicate a lack of survival of these neurons, perhaps due to the ectopic location or an inflammatory environment post-injury.

In summary, we report here that ischemic striatal injury resulting in substantial loss of striatal projection neurons does not stimulate the replacement of these cells in the adult or neonatal brain. Although it is clear from the present findings and previous reports that striatal injury can result in the appearance of new striatal neurons, on balance it appears this represents a re-direction of constitutively generated neuroblasts from the SVZ or RMS to the site of injury and not the generation of Darpp32+ striatal projection neurons. Importantly, the present study also shows that injury does not promote striatal neuron replacement even during periods of active birth of striatal projection neurons. Thus, injury itself appears to be insufficient as an extrinsic signaling pathway for regulation of otherwise highly conserved neurogenic programs. Although self-repair strategies remain a fascinating prospect for restorative neurology, successful replacement of projection neurons will likely require additional signaling components including cell-intrinsic determinants of differentiation outcome. Recent reports of forced differentiation to specific neuronal phenotypes through cell-intrinsic over-expression of neurogenic transcription factors *in vivo* ([@bib15]) suggest this may also be an interesting approach for facilitating cellular replacement after stroke.

Limitations of the Study {#sec3.1}
------------------------

•We did not include additional phenotypic markers of immature striatal projection phenotype. Although DARPP32 is regarded as definitive for mature identity, we cannot exclude an initial neurogenic response to produce striatal projection progenitors that ailed to survive.•This study does not consider injury-induced neurogenesis in other areas of the brain that can be affected by this model of stroke, for example, in the hippocampus or cortex. Thus conclusions on a general lack of capacity for "self-repair" should be limited to striatal projection neurons.

Resource Availability {#sec3.2}
---------------------

### Lead Contact {#sec3.2.1}

Charlotte Ermine, <charlotte.ermine@florey.edu.au>.

### Materials Availability {#sec3.2.2}

Requests for further information and reagents should be directed to and will be fulfilled by <charlotte.ermine@florey.edu.au> or <lachlant@unimelb.edu.au>.

### Data and Code Availability {#sec3.2.3}

Requests for further information or biological data should be directed to and will be fulfilled by <charlotte.ermine@florey.edu.au> or <lachlant@unimelb.edu.au>.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figure S1

The authors thank Mong Tien for expert technical assistance in the tissue preparation and immunohistochemical procedures. C.L.P. is an NHMRC Senior Research Fellow. This work was supported 10.13039/501100000925NHMRC project grant 1130734. The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the 10.13039/501100004752Victorian Government and in particular the funding from the Operational Infrastructure Support Grant.

Author Contributions {#sec5}
====================

C.M.E. and J.L.W. contributed to the experimental procedures and analysis. C.M.E., J.L.W., D.S., C.L.P., and L.H.T. contributed to the conception and design of the study. L.H.T. and C.M.E. wrote the manuscript. L.H.T. sourced funding for the work. All authors contributed to the manuscript revision, and read and approved the submitted version.

Declaration of Interests {#sec6}
========================

The authors declare no competing interests.

Supplemental Information can be found online at <https://doi.org/10.1016/j.isci.2020.101175>.

[^1]: Present address: Wolfson Institute for Biomedical Research, University College London, Gower Street, London WC1E 6BT, UK

[^2]: Lead Contact
